Navigation Links
New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma

Priority is collaborating effectively with government and NGO partners and strengthening the supply chain for delivering Pfizer-donated Zithromax

ATLANTA, July 1 /PRNewswire-USNewswire/ -- The International Trachoma Initiative (ITI) has a new leadership team focused on creating effective collaborations among governments and NGOs in 56 trachoma endemic countries. Through stronger partnerships, ITI hopes to support local, national, regional, and international groups in reaching the goal of eliminating blinding trachoma globally by 2020. The leadership team has extensive experience in trachoma programming and addressing Neglected Tropical Diseases (NTDs).

"We see ITI as a partner among partners in the global trachoma community," said Dr. Danny Haddad, ITI Director. "Governments and NGOs are committed to implementing the SAFE strategy -- Surgery, Antibiotics, Facial cleanliness, and Environmental improvements -- used to treat and prevent trachoma. We are setting up a Trachoma Expert Committee with experts in water, sanitation, health communications and surgery."

When ITI merged with the Task Force for Global Health in April 2009, Jeffrey B. Kindler, the Chairman and CEO of Pfizer, which supplies the antibiotic Zithromax that treats and prevents trachoma, stated, "We look forward to continuing our support and working through ITI and its Trachoma Expert Committee to provide the Zithromax that will be needed to eliminate blinding trachoma by 2020 and restore the health and well-being of families now and generations to come."

"The Zithromax drug donation program remains the key priority," said Haddad. "With this renewed commitment from Pfizer, our top goal is to make sure that Zithromax is distributed on time and in the right quantity to our partner countries."

Dr. Haddad is joined by four key staff members:

  • Associate Director Lisa Rotondo has extensive public health program management and evaluation experience, with an emphasis on trachoma and other NTDs in Africa.
  • Supply Chain Manager Vivian Singletary has worked over 15 years on managing supply chain optimization projects, including mid- to long-term strategy, IT system implementations and process improvement.
  • Project Manger PJ Hooper, who oversees a Gates Foundation grant supporting NTD integration research, has conducted operational research on Lymphatic Filariasis and NTDs for another Gates grant to the Global Alliance to Eliminate LF.
  • Program Accounting Manager Edward Nyankson has 16 years experience in accounting and financial reporting, tax, securities exchange and regulatory reporting.

ITI has program offices in Ethiopia, Ghana, Mali, Niger, Tanzania and Vietnam.

SOURCE The International Trachoma Initiative (ITI)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
2. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
3. KGI and Smith College Establish Leadership Forum for Women in Bioscience
4. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
5. Assay Designs(TM) Announces Additions to the Leadership Team
6. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
7. Dr. Dinesh Verma to be honored with Presidents Leadership Award at Edwin A. Stevens Society Gala
8. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
11. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
Post Your Comments:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
Breaking Biology News(10 mins):